HomeCompareFSK vs HOLX

FSK vs HOLX: Dividend Comparison 2026

FSK yields 18.89% · HOLX yields 2.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSK wins by $55.0K in total portfolio value
10 years
FSK
FSK
● Live price
18.89%
Share price
$9.95
Annual div
$1.88
5Y div CAGR
2.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.7K
Annual income
$8,463.51
Full FSK calculator →
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →

Portfolio growth — FSK vs HOLX

📍 FSK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSKHOLX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSK + HOLX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSK pays
HOLX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSK
Annual income on $10K today (after 15% tax)
$1,606.03/yr
After 10yr DRIP, annual income (after tax)
$7,193.98/yr
HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
At 15% tax rate, FSK beats the other by $6,927.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSK + HOLX for your $10,000?

FSK: 50%HOLX: 50%
100% HOLX50/50100% FSK
Portfolio after 10yr
$51.2K
Annual income
$4,388.76/yr
Blended yield
8.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HOLX right now

FSK
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$15.00
+50.8% upside vs current
Range: $15.00 — $15.00
Altman Z
-0.0
Piotroski
3/9
HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSK buys
0
HOLX buys
0
No recent congressional trades found for FSK or HOLX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSKHOLX
Forward yield18.89%2.65%
Annual dividend / share$1.88$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.3%0%
Portfolio after 10y$78.7K$23.6K
Annual income after 10y$8,463.51$314.03
Total dividends collected$46.6K$2.9K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldHold
Analyst price target$15.00$77.80

Year-by-year: FSK vs HOLX ($10,000, DRIP)

YearFSK PortfolioFSK Income/yrHOLX PortfolioHOLX Income/yrGap
1← crossover$12,633$1,932.90$10,965$264.73+$1.7KFSK
2$15,852$2,334.56$12,004$271.27+$3.8KFSK
3$19,762$2,800.73$13,121$277.55+$6.6KFSK
4$24,484$3,338.26$14,323$283.54+$10.2KFSK
5$30,152$3,954.17$15,615$289.27+$14.5KFSK
6$36,918$4,655.67$17,003$294.73+$19.9KFSK
7$44,952$5,450.05$18,493$299.93+$26.5KFSK
8$54,444$6,344.63$20,093$304.87+$34.4KFSK
9$65,601$7,346.71$21,809$309.57+$43.8KFSK
10$78,657$8,463.51$23,649$314.03+$55.0KFSK

FSK vs HOLX: Complete Analysis 2026

FSKBDC

FS KKR Capital Corp. is a business development company specializing in investments in debt securities. It provides customized credit solutions to private middle market U.S. companies. It invest primarily in the senior secured debt and, to a lesser extent, the subordinated debt of private middle market U.S. companies. It seeks to purchase interests in loans through secondary market transactions or directly from the target companies as primary market investments. It also seeks to invest in first lien senior secured loans, second lien secured loans and, to a lesser extent, subordinated loans, or mezzanine loans. In connection with the debt investments, the firm also receives equity interests such as warrants or options as additional consideration. It also seek to purchase minority interests in the form of common or preferred equity in our target companies, either in conjunction with one of the debt investments or through a co-investment with a financial sponsor. Additionally, on an opportunistic basis, the fund may also invest in corporate bonds and similar debt securities. The fund does not seek to invest in start-up companies, turnaround situations, or companies with speculative business plans. It seeks to invest in small and middle-market companies based in United States. The fund seeks to invest in firms with annual revenue between $10 million to $2.5 billion. It focus on providing customized one-stop credit solutions to private upper middle market companies with annual EBITDA of $50 million to $100 million at the time of investment. It seeks to exit from securities by selling them in a privately negotiated over- the- counter market. For any investments that are not able to be sold within the secondary market, the firm seeks to exit such investments through repayment, an initial public offering of equity securities, merger, sale or recapitalization.

Full FSK Calculator →

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →
📬

Get this FSK vs HOLX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSK vs SCHDFSK vs JEPIFSK vs OFSK vs KOFSK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.